Finanzen von Bicara Therapeutics Inc (BCAX)BCAXBicara Therapeutics Inc

Evaluating the bottom line, Bicara Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -41.01%, provide a clear picture of how effectively BCAX converts its operational activities into shareholder value.

In the context of the broader market, BCAX competes directly with industry leaders such as AVLN and AMPH. With a market capitalization of $1.17B, it holds a significant position in the sector. When comparing efficiency, BCAX's gross margin of N/A stands against AVLN's N/A and AMPH's 50.83%. Such benchmarking helps identify whether Bicara Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Bicara Therapeutics has reported significant net losses, including a loss of $56.2 million in Q1 2026 and a negative EPS of -0.82 for Q2 2026. The company has a current ratio of 11.59, indicating it can cover its short-term liabilities, but the trend of increasing losses is concerning.